Table 4.
Univariate and multivariate analyses of the prognostic factors of overall survival (OS) in the training cohort.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P- value | |
| Age, years (<55/≥55) | 1.198 | 0.986-1.456 | 0.070 | |||
| Gender (Male/Female) | 1.044 | 0.853-1.277 | 0.676 | |||
| ECOG PS score (0/1-2) | 1.184 | 0.971-1.443 | 0.095 | |||
| Primary tumor site ( Left /Right) | 1.477 | 1.185-1.841 | 0.001 | 1.437 | 1.175-1.757 | < 0.001 |
| Tumor grade (G1-2/G3) | 1.410 | 1.128-1.762 | 0.003 | 1.565 | 1.245-1.966 | < 0.001 |
| Number of metastatic organs (1/≥2) | 0.937 | 0.768-1.143 | 0.521 | |||
| Primary/Metastatic tumor resection (Yes/No) | 1.443 | 1.185-1.758 | 0.001 | 1.473 | 1.175-1.757 | < 0.001 |
| Chemotherapy (Chemo/combination) | 0.960 | 0.776-1.187 | 0.705 | |||
| CEA (ng/ml) (<5/≥5) | 1.692 | 1.364-2.100 | < 0.001 | 1.501 | 1.193-1.889 | 0.001 |
| CA19-9 (ng/ml) (<35/≥35) | 1.569 | 1.289-1.911 | < 0.001 | 1.317 | 1.065-1.630 | 0.011 |
| Cholesterols (mmol/L) (≤6.47/>6.47) | 1.375 | 1.033-1.8230 | 0.006 | |||
| Triglycerides (mmol/L) (≤1.70/>1.70) | 0.789 | 0.625-0.996 | 0.046 | 0.707 | 0.558-0.896 | 0.004 |
| HDL-C (mmol/L) (≥0.78/<0.78) | 1.415 | 1.064-1.882 | 0.017 | |||
| LDL-C (mmol/L) (≤3.40/>3.40) | 1.266 | 1.041-1.540 | 0.018 | |||
| ApoA-I(ng/L) (≥1.05/<1.05) | 1.124 | 0.917-1.378 | 0.260 | |||
| ApoB (ng/L) (≤1.15/>1.15) | 1.123 | 0.984-1.496 | 0.071 | |||
| LDL-C/HDL-C (<2.55/≥2.55) | 1.340 | 1.087-1.651 | 0.006 | 1.334 | 1.109-1.746 | 0.036 |
| ApoB/ApoA-I (<0.69/≥0.69) | 1.580 | 1.234-2.023 | < 0.001 | 1.371 | 1.205-1.870 | 0.045 |
* ECOG PS score: Eastern Cooperative Oncology Group performance status score; CEA: serum carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; LDL-C/HDL-C: LDL-C to HDL-C ratio; ApoB/ApoA-I: ApoB to ApoA-I ratio.